Gianna Melillo


Farxiga, Developed for Diabetes, Gets FDA Nod for Heart Failure

May 07, 2020

The FDA recently approved AstraZeneca’s Farxiga (dapagliflozin) for the treatment of heart failure with reduced ejection fraction (HFrEF) in adults with and without type 2 diabetes, marking the first time a drug in a class developed for diabetes was approved for heart failure even if diabetes is not present.